View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 24, 2021updated 12 Jul 2022 11:21am

Frequency’s Phase IIa hearing loss trial shows no benefit versus placebo

Day-90 data from a Phase IIa study of four dosing regimens of Frequency Therapeutics’ hearing loss treatment FX-322 in subjects with mild to moderately severe sensorineural hearing loss (SNHL) “did not demonstrate improvements in hearing measures versus placebo”, according to a company statement.  

By Kezia Parkins

Day-90 data from a Phase IIa study of four dosing regimens of Frequency Therapeutics’ hearing loss treatment FX-322 in subjects with mild to moderately severe sensorineural hearing loss (SNHL) “did not demonstrate improvements in hearing measures versus placebo”, according to a company statement.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The disappointing results caused the company’s stock to drop as much as 72% in premarket trading on Tuesday morning. The data comes after the treatment achieved positive results in a Phase I trial testing a single dose regimen.

FX-322, Frequency’s front-running product candidate, is designed to trigger dormant progenitor cells in the ear to encourage the growth of new hair cells in the cochlea that are responsible for sensing and translating sound.

The Phase IIa trial was meant discern whether repeat dosing could enhance the effects of FX-322.

In the four-arm Phase IIa study, 95 subjects aged 18-65 were assessed for hearing improvement using Word Recognition (WR), Words-In-Noise (WIN), pure tone audiometry and other exploratory measures. All participants were dosed with a total of four weekly intratympanic injections in the eardrum. Some patients received four placebo shots or four shots of FX-322, while others received one, two or three doses of the drug, with placebo making up the remaining doses.

While WR scores improved across the board for all groups, repeated weekly injections were found to dampen the hearing benefit observed compared to previous single-injection studies.

Frequency stated there was no discernible hearing benefit of FX-322 over placebo in the trial.

The Phase IIa interim results also revealed an unexpected ostensible level of hearing benefit in the placebo group unseen in previous trials, indicating flaws and potential bias in the trial design.

“Patients, our subjects, they desperately need hearing solutions,” said the firm’s senior vice president of strategic marketing and new product planning Kevin Franck, PhD, as reported by Fierce Biotech. “When we communicated there were entry criteria of a depressed word score, we may have induced an unconscious bias in subjects who wanted to get into the trial.”

Despite the surprising results of the study, Frequency remains positive about its lead candidate.

“Our FX-322 interim Phase 2a clinical results were unexpected, especially given our prior published Phase 1/2 data. We have already gained important learnings from this study that will inform our future development efforts,” said Frequency’s president and chief executive officer David L. Lucchino.

“The results clearly demonstrated that a treatment regimen using four weekly injections is unfavourable and we will continue to move ahead with single-dose administrations in future studies. We believe in the potential of FX-322 given the demonstrated hearing signal and favourable safety profile observed with a single dose and in the future, we may evaluate re-treatment at longer intervals.”

The company also revealed confidence-boosting early results from a Phase Ib study in 33 patients with mild to moderate sensorineural hearing loss who received a dose of FX-322 in one ear, with the untreated ear as the control. 90 days after treatment, 34% of the patients logged a 10% or greater improvement in word recognition scores in their treated ear compared to the untreated ear.

Frequency plans to work through bias issues in its trial design, and is waiting on final results from the Phase IIa study as well as readouts from two more Phase Ib studies, which will inform next steps.

Final results from the Phase IIa trial will be reported in late Q2 2021, the company said.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena